Y Intercept Hong Kong Ltd Purchases Shares of 23,497 AnaptysBio, Inc. (NASDAQ:ANAB)

Y Intercept Hong Kong Ltd bought a new stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 23,497 shares of the biotechnology company's stock, valued at approximately $311,000. Y Intercept Hong Kong Ltd owned approximately 0.08% of AnaptysBio as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in ANAB. China Universal Asset Management Co. Ltd. increased its holdings in shares of AnaptysBio by 11.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company's stock worth $85,000 after buying an additional 644 shares in the last quarter. Point72 DIFC Ltd boosted its stake in AnaptysBio by 680.5% in the third quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company's stock worth $205,000 after purchasing an additional 5,342 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of AnaptysBio by 35.0% during the fourth quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company's stock worth $216,000 after purchasing an additional 4,231 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of AnaptysBio in the third quarter valued at $229,000. Finally, Janus Henderson Group PLC bought a new position in shares of AnaptysBio in the third quarter valued at about $250,000.

Analysts Set New Price Targets

ANAB has been the subject of several research reports. Wedbush restated an "outperform" rating and issued a $40.00 price objective on shares of AnaptysBio in a research report on Wednesday, February 12th. HC Wainwright reissued a "neutral" rating and issued a $22.00 price target on shares of AnaptysBio in a report on Tuesday. Wells Fargo & Company upped their price objective on AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Truist Financial decreased their price objective on AnaptysBio from $30.00 to $20.00 and set a "hold" rating on the stock in a research report on Wednesday, December 18th. Finally, Wolfe Research initiated coverage on AnaptysBio in a research report on Tuesday, February 4th. They set an "outperform" rating and a $25.00 target price for the company. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $35.11.

Remove Ads

AnaptysBio Trading Down 0.7 %

Shares of NASDAQ:ANAB traded down $0.12 during midday trading on Friday, hitting $16.28. The company had a trading volume of 285,173 shares, compared to its average volume of 1,041,373. AnaptysBio, Inc. has a 12 month low of $12.21 and a 12 month high of $41.31. The firm has a fifty day simple moving average of $16.16 and a 200 day simple moving average of $24.22. The stock has a market cap of $495.38 million and a price-to-earnings ratio of -2.68.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.61) by $0.89. The firm had revenue of $43.11 million for the quarter, compared to analysts' expectations of $10.17 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. Equities analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

Insider Activity at AnaptysBio

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 6,646 shares of AnaptysBio stock in a transaction on Thursday, January 2nd. The shares were purchased at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the acquisition, the director now owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. The trade was a 0.08 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 33.70% of the company's stock.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.